Category: NAFLD Prevalence

All Podcast Categories
S4-33.2 - Unmet Needs in the Primary Care Setting for Disease Identification

S4-33.2 – Unmet Needs in the Primary Care Setting for Disease Identification

Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss the presentations of interest from EASL Congress 2023. In this conversation, Ian points to a presentation on automated FIB-4 score calculation and e-reminders to detect advanced liver disease in patients with type 2 diabetes. The group goes on to explore big picture questions on the topic of disease identification and tease the differences between hepatology and private practices and management of a population-level disease.

S4-33.1 - EASL Congress 2023: Focus on New Nomenclature

S4-33.1 – EASL Congress 2023: Focus on New Nomenclature

Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss the new NAFLD/NASH nomenclature shared at EASL Congress 2023. The groups outlines what the changes entail and shares practical considerations around how to implement the changes in different settings and with patients.

S4-33 - EASL Congress: Nomenclature and More Compelling Presentations

S4-33 – EASL Congress: Nomenclature and More Compelling Presentations

Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss critical and/or compelling presentations and insights from the recently concluded EASL Congress in Vienna. The session focuses on new nomenclature and emerging stories around patient identification, NITs, fibrosis resolution and more.

S2-5 - Key Insights from the American Diabetes Association 83rd Scientific Sessions

S2-5 – Key Insights from the American Diabetes Association 83rd Scientific Sessions

Ken Cusi and Roger Green are joined by family practice researcher and KOL Eric Johnson and diabetologist and primary care KOL Jay Shubrook in a discussion around exciting news emerging from the ADA 83rd Scientific Sessions meeting. Layering in practical takeaways, the group explores their impressions from the meeting, the utility of FIB-4 as a frontline screening tool, guidelines and recommendations, therapeutic options both now and in the imminent future, and lastly the new nomenclature rollout for Fatty Liver disease.

S4-32 - Drug Development Stories from EASL and ADA: Part 1

S4-32 – Drug Development Stories from EASL and ADA: Part 1

Stephen Harrison and Jörn Schattenberg join Roger Green to discuss newly released Phase 3 MAESTRO-NASH data on resmetirom and the wider NASH therapeutic landscape, AI-assisted digital pathology, what the field understands about liver volume reduction, an increasing burden of cirrhosis and much more. This episode is packed with robust analysis and insights stemming from a busy past month at the EASL Congress and ADA Scientific Sessions meetings.

S4-27.3 - Abstract session - NAFLD: Clinical Aspects

S4-27.3 – Abstract session – NAFLD: Clinical Aspects

This conversation covers final thoughts on the anticipations of Ian Rowe, Jörn Schattenberg and Roger Green heading into EASL Congress 2023. The group primarily explores a session on NAFLD clinical aspects which provides practical presentations around tools available now for treating and managing patients with NASH.

S4-27.2 - Abstract session - NAFLD: Therapy

S4-27.2 – Abstract session – NAFLD: Therapy

This conversation with Ian Rowe, Jörn Schattenberg and Roger Green continues to unpack the rich EASL Congress 2023 program by discussing abstracts and presentations of interest. The group dives deep into liver science with commentary around emerging developments in NAFLD/NASH therapeutics.

S4-27.1 - Unpacking the Program with Ian Rowe and Jörn Schattenberg

S4-27.1 – Unpacking the Program with Ian Rowe and Jörn Schattenberg

This conversation with Ian Rowe, Jörn Schattenberg and Roger Green begins to unpack the rich EASL Congress 2023 program and explore in detail presentations of interest. Specifically, the group dives into anticipations around an abstract session around diagnostics and non-invasive assessment.

Sponsoring Partnerships

Sponsoring partnerships with SurfingMASH present a multifaceted avenue for companies seeking to amplify their brand presence and engage with targeted audiences.